Drugs / Soquelitinib
Trials 6
News releases announcing trial results or a regulatory action · 41
| Date | Issuer | Release |
|---|---|---|
| 2026-08-27 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial corvuspharma.com ↗
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of peer-reviewed final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma. |
| 2026-05-14 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting corvuspharma.com ↗
New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. |
| 2026-03-12 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results corvuspharma.com ↗
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy |
| 2026-01-20 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis corvuspharma.com ↗
Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced positive results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. |
| 2025-12-08 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial corvuspharma.com ↗
The Phase 1 data demonstrate impressive progression free and overall survival in relapsed/refractory patients treated with soquelitinib. |
| 2025-08-07 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results corvuspharma.com ↗
Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8 |
| 2025-06-25 | Corvus Pharmaceuticals, Inc. | Regulatory Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis corvuspharma.com ↗ |
| 2025-06-04 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis corvuspharma.com ↗
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. |
| 2025-05-08 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results corvuspharma.com ↗
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 |
| 2025-05-08 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis corvuspharma.com ↗
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. |
| 2025-03-25 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results corvuspharma.com ↗
The results from the first two cohorts demonstrated safety and activity compared to placebo utilizing the rigorous endpoint of EASI 75 and IGA 0 or 1. |
| 2025-03-20 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma corvuspharma.com ↗ |
| 2025-01-13 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis corvuspharma.com ↗
The data, which include previously reported results from cohort 1 of the trial and new data covering 10 patients with 28-day follow-up from cohort 2 of the trial, demonstrated a favorable safety profile and efficacy profile. |
| 2024-12-18 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis corvuspharma.com ↗
Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. |
| 2024-12-04 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity corvuspharma.com ↗
The data also shows that soquelitinib increases effector function of cytotoxic CD8 positive T cells and leads to an increase in memory T cells with enhanced effector function. |
| 2024-11-14 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis corvuspharma.com ↗
Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data highlighting the potential of soquelitinib, the Company’s lead ITK inhibitor program, to prevent lung damage, inflammation and pulmonary hypertension caused by systemic sclerosis. |
| 2024-08-06 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results corvuspharma.com ↗
Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels Consistent with ITK Inhibition Mechanism of Action |
| 2024-08-01 | Corvus Pharmaceuticals, Inc. | Regulatory Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) corvuspharma.com ↗ |
| 2024-07-25 | Corvus Pharmaceuticals, Inc. | Results Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases corvuspharma.com ↗
Researchers at Cornell utilized soquelitinib (formerly CPI-818), the Company’s selective ITK inhibitor, to demonstrate in vitro and in vivo that ITK inhibition induces switching of proinflammatory Th 17 cells into anti-inflammatory T reg suppressor cells. |
| 2024-05-06 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results corvuspharma.com ↗
We are encouraged that two newly evaluable PTCL patients from the soquelitinib Phase 1 trial achieved objective responses – one complete response and one partial response – as we move forward with our plans for a registration Phase 3 trial that is on track to be initiated in the third quarter. |
| 2024-03-19 | Corvus Pharmaceuticals, Inc. | Regulatory Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results corvuspharma.com ↗
We believe we are well positioned to execute on this trial, with recent positive updates from our Phase 1/1b clinical trial, alignment on the final study protocol with FDA, interest from leading academic centers in North America , and the receipt of Orphan Drug Designation for soquelitinib. |
| 2024-02-12 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases corvuspharma.com ↗
These results suggest that chemical structures may be refined to perform more specific biologic functions and may enable targeting of various disease types. |
| 2024-02-08 | Corvus Pharmaceuticals, Inc. | Regulatory Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma corvuspharma.com ↗
Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for soquelitinib for the treatment of T cell lymphoma. |
| 2023-12-09 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial corvuspharma.com ↗
Soquelitinib demonstrated durable anti-tumor activity, evidenced by progression free survival, duration of response and overall survival rates that exceed current standard of care therapies for patients with relapsed PTCL. |
| 2023-11-01 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases corvuspharma.com ↗
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data that demonstrated the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases. |
| 2023-07-06 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818) corvuspharma.com ↗ |
| 2023-06-15 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma corvuspharma.com ↗
The data includes updated interim results from the CPI-818 Phase 1/1b clinical trial that continues to demonstrate the potential of ITK inhibition and the absolute lymphocyte count (ALC) biomarker in T cell lymphoma (TCL). |
| 2023-05-08 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results corvuspharma.com ↗
We are generating encouraging clinical data from our ongoing Phase 1/1b trial with meaningful objective responses seen in patients with multiply recurrent T cell lymphomas. |
| 2023-04-17 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting corvuspharma.com ↗
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced new data for CPI-818, the Company’s ITK inhibitor, demonstrating its potential to treat a variety of solid and hematological cancers based on a novel immunotherapy mechanism of action. |
| 2023-04-03 | Corvus Pharmaceuticals, Inc. | Results CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma corvuspharma.com ↗
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced interim data demonstrating the potential of CPI-818, the Company’s ITK inhibitor, for the treatment of T cell lymphoma (TCL) at the 10 th Whistler Global Summit on Hematologic Malignancies, which took place March 29 to April 2, 2023 in Whistler British Columbia , Canada. |
| 2023-03-28 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results corvuspharma.com ↗
New CPI-818 Predictive Biomarker Enables Selection of Lymphoma Patients Most Likely to Benefit from Treatment |
| 2023-03-14 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting corvuspharma.com ↗
The data demonstrates that in a murine syngeneic CT26 colon cancer model, single-agent CPI-818 showed anti-tumor activity, and when CPI-818 was combined with suboptimal doses of anti-PD1 and anti-CTLA4 therapy, 100% of treated animals achieved complete tumor elimination. |
| 2023-02-21 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal corvuspharma.com ↗
today announced new data demonstrating the potential of CPI-818, the Company’s ITK inhibitor, to reduce the need for chronic human immunodeficiency virus (HIV) therapy. |
| 2022-12-12 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition corvuspharma.com ↗
We have seen durable objective tumor responses in four of eleven evaluable patients. |
| 2022-05-10 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Provides Program Updates at R&D Symposium corvuspharma.com ↗
Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas |
| 2021-12-13 | Corvus Pharmaceuticals, Inc. | Results New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation corvuspharma.com ↗ |
| 2021-10-27 | Corvus Pharmaceuticals, Inc. | Regulatory Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China corvuspharma.com ↗ |
| 2021-08-16 | Corvus Pharmaceuticals, Inc. | Regulatory Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China corvuspharma.com ↗ |
| 2020-12-06 | Corvus Pharmaceuticals, Inc. | Results Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & Exposition corvuspharma.com ↗
Our Phase 1/1b trial in T cell lymphomas has identified a dose of CPI-818 that was well tolerated, covalently inhibited ITK and demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies. |
| 2020-02-01 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1/1b Clinical Trial of CPI-818 at the 12th Annual T-Cell Lymphoma Forum corvuspharma.com ↗
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated results from its Phase 1/1b clinical trial of CPI-818, the Company’s ITK-inhibitor, which were presented today in an oral presentation at the 12 th Annual T-Cell Lymphoma Forum in La Jolla, California , taking place January 30 to February 1, 2020 . |
| 2019-12-07 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting corvuspharma.com ↗
The early clinical data from the study demonstrated specific target engagement by CPI-818. |
All press releases naming this drug 61 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Soquelitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07441395 ↗ |
| Known as | CP-000596 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5817577 ↗ |
| Known as | CP-596 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5817577 ↗ |
| Known as | CPI-000818 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5817577 ↗ |
| Known as | CPI-596 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5817577 ↗ |
| Known as | CPI-818 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03952078 ↗ |
| Action | Inhibit | “CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor” NCT03952078 ↗ |
| Modality | Small molecule | — CHEMBL5817577 ↗ |
| Route | Oral | “Participants will receive CPI-818 capsule, orally, twice per day” NCT03952078 ↗ |
| Target | ITK | “CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor” NCT03952078 ↗ |